Stanford Researchers cite BioPharm Laboratories High Purity Thrombin
February 10, 2022
More accolades for BioUtah member BioPharm Laboratories – another journal article from the Journal of Biological Chemistry cites the use of BioPharm’s High Purity Thrombin being used to cleave protein in their protein purification process. This time from researchers at Stanford University.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic trait that can cause hemolytic anemia. To date, over 150 non-synonymous mutations have been identified in G6PD, with pathogenic mutations clustering near the dimer and/or tetramer interface and the allosteric NADP+-binding site. BioPharm has identified a small molecule which activates G6PD variants by stabilizing the allosteric NADP+ and dimer complex, suggesting therapeutics that target these regions may improve structural defects.
Recent News
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
- Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
- Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
- GE HealthCare’s Economic Impact Across Utah
- RefloDx Wins Trans Atlantic Angel Grand Prize